A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1758-9193
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease ; volume:9 ; number:1 ; day:8 ; month:12 ; year:2017 ; pages:1-15 ; date:12.2017
Alzheimer's research & therapy ; 9, Heft 1 (8.12.2017), 1-15, 12.2017

Classification
Medizin, Gesundheit

Contributor
Ostrowitzki, Susanne
Lasser, Robert A.
Dorflinger, Ernest
Scheltens, Philip
Barkhof, Frederik
Nikolcheva, Tania
Ashford, Elizabeth
Retout, Sylvie
Hofmann, Carsten
Delmar, Paul
Klein, Gregory
Andjelkovic, Mirjana
Dubois, Bruno
Boada, Mercè
Blennow, Kaj
Santarelli, Luca
Fontoura, Paulo
SpringerLink (Online service)

DOI
10.1186/s13195-017-0318-y
URN
urn:nbn:de:1111-20180210647
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Ostrowitzki, Susanne
  • Lasser, Robert A.
  • Dorflinger, Ernest
  • Scheltens, Philip
  • Barkhof, Frederik
  • Nikolcheva, Tania
  • Ashford, Elizabeth
  • Retout, Sylvie
  • Hofmann, Carsten
  • Delmar, Paul
  • Klein, Gregory
  • Andjelkovic, Mirjana
  • Dubois, Bruno
  • Boada, Mercè
  • Blennow, Kaj
  • Santarelli, Luca
  • Fontoura, Paulo
  • SpringerLink (Online service)

Other Objects (12)

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease

Heterogeneity of Alzheimer’s disease: consequence for drug trials?

Heterogeneity of Alzheimer’s disease: consequence for drug trials?

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

A decade of Alzheimer’s Research & Therapy: reflections on the past, present, and future

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress

The “rights” of precision drug development for Alzheimer’s disease

The “rights” of precision drug development for Alzheimer’s disease

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics

Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury

Clinical Features of Patients with Alzheimer’s Disease and a History of Traumatic Brain Injury

Fluid biomarkers in Alzheimer’s disease – current concepts

Fluid biomarkers in Alzheimer’s disease – current concepts

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders

Related objects